Lantern Pharma (LTRN) Stock Price, News & Analysis

Company Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $4.00 to $4.60
• 50-Day Range: $3.05 to $5.32
• 52-Week Range: $2.55 to $6.12
• Volume: 159,863 shs
• Average Volume: 143,257 shs
• Market Capitalization: $49.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Buy

Lantern Pharma Stock Analysis - MarketRank™

Lantern Pharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 607th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lantern Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lantern Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lantern Pharma are expected to grow in the coming year, from ($1.90) to ($1.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantern Pharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantern Pharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lantern Pharma has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.54% of the float of Lantern Pharma has been sold short.

Short Interest Ratio / Days to Cover

Lantern Pharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lantern Pharma has recently decreased by 2.73%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantern Pharma does not currently pay a dividend.

Dividend Growth

Lantern Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.54% of the float of Lantern Pharma has been sold short.

Short Interest Ratio / Days to Cover

Lantern Pharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lantern Pharma has recently decreased by 2.73%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.57

News Sentiment

Lantern Pharma has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lantern Pharma this week, compared to 1 article on an average week.

Search Interest

12 people have searched for LTRN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lantern Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,000,580.00 in company stock.

Percentage Held by Insiders

Only 7.31% of the stock of Lantern Pharma is held by insiders.

Percentage Held by Institutions

Only 28.62% of the stock of Lantern Pharma is held by institutions.

LTRN Stock Analysis - Frequently Asked Questions

How have LTRN shares performed this year?

Lantern Pharma's stock was trading at $3.19 at the beginning of 2025. Since then, LTRN shares have increased by 43.3% and is now trading at $4.57.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) released its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.13.

When did Lantern Pharma IPO?

Lantern Pharma (LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Who are Lantern Pharma's major shareholders?

Top institutional investors of Lantern Pharma include BIOS Capital Management LP (9.98%), NewEdge Advisors LLC (0.52%), Westside Investment Management Inc. (0.33%) and XTX Topco Ltd (0.12%). Insiders that own company stock include Leslie W Kreis and Aaron GL Fletcher.
View institutional ownership trends.

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/14/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LTRN
• CIK: 1763950
• Web: www.lanternpharma.com
• Phone: 972-277-1136
• Fax: N/A
• Employees: 20
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Lantern Pharma: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +425.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.78 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -83.26%
• Return on Assets: -70.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.86
• Quick Ratio: 4.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.96 per share
• Price / Book: 2.43

Miscellaneous

• Outstanding Shares: 10,780,000
• Free Float: 9,997,000
• Market Cap: $51.31 million
• Optionable: Optionable
• Beta: 1.60